Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray

Yaoxue Xuebao

Volumn 40, Issue 8, 2005, Pages 695-699

  Li, Jian ^a,b   Wen, Si Yuan ^a   Wang, Rui ^b   Chen, Kun ^b   Fang, Yi ^b   Pei, Fei ^b   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Allele; Cytochrom P450 CYP2C9; Genotyping; Single nucleotide polymorphism; Tolbutamide

Indexed keywords

CYP2C9 PROTEIN, HUMAN; TOLBUTAMIDE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DNA MICROARRAY; GENETICS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; RANDOMIZATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOM ALLOCATION; TOLBUTAMIDE;

EID: 26844546679     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Blakey GE, Lockton JA, Perrett J, et al. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1 [J]. Br J Clin Pharmacol, 2004, 57(2):162-169.
2. Kirchheiner J, Meineke I, Muller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers [J]. Clin Pharmacokinet, 2004, 43(4):267-278.
3. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9 * 3 [J]. Clin Pharmacol Ther, 2001, 70(4):391-394.
4. Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral Vitamin K on S- and R- warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe [J]. J Clin Pharmacol, 2001, 41(7):715-722.
5. Daly AK, King BP. Pharmacogenetics of oral anticoagulants [J]. Pharmacogenetics, 2003, 13(5):247-252.
6. Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9 * 3 allele [J]. Pharmacogenetics, 1999, 9(1):71-80.
7. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data [J]. Pharmacogenetics, 2002, 12(3):251-263.
8. Freeman BD, Zehnbauer BA, McGrath S, et al. Cytochrome P450 polymorphisms are associated with reduced warfarin dose [J]. Surgery, 2000, 128(2):281-285.
9. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements [J]. Br J Clin Pharmacol, 2002, 53(4):408-409.
10. Wen SY, Wang H, Sun OJ, et al. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray [J]. World J Gastroenterol, 2003, 9(6):1342-1346.
11. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 [J]. Clin Pharmacokinet, 1995, 29(3):192-209.
12. Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population [J]. Br J Clin Pharmacol, 2001, 51(3):277-280.
13. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9 * 5) expressed among African Americans [J]. Mol Pharmacol, 2001, 60(2):382-387.